A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
From MaRDI portal
Publication:6076490
Recommendations
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- A Bayesian adaptive design for two-stage clinical trials with survival data
- A Bayesian Approach to the Design of Phase II Clinical Trials
- Bayesian adaptive designs for clinical trials
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
- A Bayesian adaptive design for clinical trials in rare diseases
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints
- Bayesian adaptive methods for clinical trials
Cites work
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Continual reassessment method for ordered groups
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Dose-finding designs for HIV studies
- scientific article; zbMATH DE number 47310 (Why is no real title available?)
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
- Robust EM continual reassessment method in oncology dose finding
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- The Calculation of Posterior Distributions by Data Augmentation
Cited in
(7)- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- An adaptive trial design to optimize dose-schedule regimes with delayed outcomes
- A combined proof of concept and dose finding study with multiple endpoints: A Bayesian adaptive design in chronic prostatitis/chronic pelvic pain syndrome
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- Seamless phase I/II design for novel anticancer agents with competing disease progression
- Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
This page was built for publication: A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6076490)
